| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jan, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(6 years from now) | |
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(12 years from now) | |
Xospata is owned by Astellas.
Xospata contains Gilteritinib Fumarate.
Xospata has a total of 3 drug patents out of which 0 drug patents have expired.
Xospata was authorised for market use on 28 November, 2018.
Xospata is available in tablet;oral dosage forms.
Xospata can be used as treatment of acute myeloid leukemia (aml).
Drug patent challenges can be filed against Xospata from 28 November, 2022.
The generics of Xospata are possible to be released after 01 July, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-222) | Nov 28, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Treatment of acute myeloid leukemia (aml)
Dosage: TABLET;ORAL
How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage
XOSPATA family patents
